Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Starting Treatment With Agonist Replacement Therapies (START)

This study has been completed.
Sponsor:
Collaborator:
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
Walter Ling, University of California, Los Angeles
ClinicalTrials.gov Identifier:
NCT00315341
First received: April 16, 2006
Last updated: November 9, 2016
Last verified: November 2016
  Purpose
The Food and Drug Administration (FDA) has requested a study comparing buprenorphine/naloxone (BUP/NX) and methadone (MET) on indices of hepatic safety.

Condition Intervention Phase
Opiate-related Disorders
Drug: Buprenorphine/naloxone
Drug: Methadone
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Starting Treatment With Agonist Replacement Therapies (START)

Resource links provided by NLM:


Further study details as provided by University of California, Los Angeles:

Primary Outcome Measures:
  • Hepatic Safety [ Time Frame: 24 Weeks ]

    Participants were categorized according liver transaminase (ALT, AST) levels in blood comparing the baseline sample to any and all subsequent samples in the following manner:

    A: both ALT and AST started at less than or equal to two times the ULN and remained at two times or less ULN throughout the study

    B: either ALT or AST started at less than or equal to 2 x ULN and at any point in study exceeded 2 x ULN

    C: Either ALT or AST started > 2 x ULN, decreased (both ALT and AST) to < 2 x ULN, and remained < 2 x ULN

    D: Either ALT or AST started > 2 x ULN and remained above 2 x ULN throughout the study



Enrollment: 1269
Study Start Date: April 2006
Study Completion Date: August 2010
Primary Completion Date: August 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Buprenorphine/Nx
For the BUP/NX group, all participants will receive up to 16 mg BUP/4 mg NX on day 1 and up to 32 mg BUP/8 mg NX on day 2. It is recommended that dose changes be made in 2 to 8 mg buprenorphine increments, with the range of allowable daily doses between 2 mg and 32 mg starting on day 3 and thereafter according to clinical impression and depending upon the participant's clinical need. Investigators are encouraged to dose adequately to decrease craving and to obtain negative urine toxicology specimens.
Drug: Buprenorphine/naloxone
Participants receive up to 16 mg BUP/4 mg NX on day 1 and up to 32 mg BUP/8 mg NX on day 2. It is recommended that dose changes be made in 2 to 8 mg increments, with the range of allowable daily doses between 2 mg and 32 mg starting on day 3 and thereafter according to clinical impression and depending upon the participant's clinical need.
Active Comparator: Methadone
For the MET group, all participants will receive a maximum of 30 mg for the first dose and a maximum of 40 mg on Day 1. It is recommended that participants receive a dose on day 2 that is 10 mg higher than their total day 1 dose, and a dose on day 3 that is 10 mg higher than their total day 2 dose, unless, in the clinical judgment of the physician, a slower induction is needed. Doses will be adjusted on Day 4 and thereafter according to clinical impression and depending upon the participant's clinical need with no specific upper limit. Investigators are encouraged to dose adequately to decrease craving and to obtain negative urine toxicology specimens.
Drug: Methadone
Participants will receive a maximum of 30 mg for the first dose and a maximum of 40 mg on Day 1. It is recommended that participants receive a dose on day 2 that is 10 mg higher than their total day 1 dose, and a dose on day 3 that is 10 mg higher than their total day 2 dose, unless, in the clinical judgment of the physician, a slower induction is needed. Doses will be adjusted on Day 4 and thereafter according to clinical impression and depending upon the participant's clinical need with no specific upper limit.

Detailed Description:
This is a randomized, open-label, multi-center, Phase 4 study to assess the changes in liver enzymes related to treatment with buprenorphine/naloxone (BUP/NX) and methadone (MET) in participants entering opioid agonist treatment. Randomization will be stratified, within site, according to normal versus abnormal screening liver function tests. Participants meeting entry criteria will be dosed for 24 weeks during the active phase of the study with assessment of liver function at weeks 1, 2, 4, 8, 12, 16, 20, 24 and with follow-up assessments at week 32. Clinicians will be encouraged to treat with adequate doses of BUP/NX and MET.
  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Were age 18 years or older,
  2. Met DSM-IV-TR criteria for opioid dependence,
  3. Were in good general health, or, in case of a medical/psychiatric condition requiring ongoing treatment, were under the care of a physician willing to continue participant's medical management and cooperate with study physicians,
  4. For female participants, use of one of the following acceptable methods of birth control:

    1. oral contraceptives
    2. barrier (diaphragm or condom) with spermicide
    3. IUD
    4. intrauterine progesterone contraceptive system
    5. levonorgestrel implant
    6. medroxyprogesterone acetate contraceptive injection
    7. contraceptive transdermal patch
    8. hormonal vaginal contraceptive ring
    9. surgical sterilization
    10. complete abstinence from sexual intercourse
  5. Able to read and verbalize understanding of the study and voluntarily sign study informed consent form.

Exclusion Criteria:

  1. ALT or AST values > 5 times the upper limit of normal as per testing laboratory range criteria,
  2. ALP values >3 times the upper limit of normal per testing laboratory criteria,
  3. Any documented past or present history of ascites, presence of esophageal or gastric varices, hepatic encephalopathy or other signs of significant liver disease as indicated by a Model for Endstage Liver Disease score (Kamath et al., 2001) of ≥11,
  4. Total bilirubin > 2.0 mg/dl (participants with documented Gilbert's syndrome were not excluded based on this criterion),
  5. Prothrombin time more than 3 seconds prolonged,
  6. Albumin level less than 2.5 g/dl,
  7. Any cardiopathy or risk factor listed below without evidence of a normal ECG* with report performed within 6 months prior to first study medication dose,

    1. Congestive heart failure
    2. Left ventricular hypertrophy
    3. Bradycardia
    4. Hereditary QT prolongation
    5. Uncorrected electrolyte imbalance
    6. Concomitant medications that are known to have a risk of QT interval prolongation; refer to Appendix D for a list of medications.

    Note: The list was not all-inclusive.

    *An ECG was abnormal if one or more of the following occurred:

    Significant ST segment abnormalities:

    • ST segment elevations in two or more continuous leads of > 0.1 mV
    • ST segment depression of greater than 1 mm that are flat or down-sloping at 80 msec after the J point ST segment abnormalities identified as "non-specific" are acceptable. If a potential participant's ECG indicated ST segment elevations or depression consistent with ischemia, the physician obtained a medical history of cardiac symptoms and referred the participant for evaluation.

    Conduction abnormalities:

    • Mobitz II 2nd degree or 3rd degree heart block
    • Atrial fibrillation, atrial flutter, or any non-sinus tachyarrhythmia
    • Three or more consecutive ectopic ventricular complexes at a rate of > 100 per minute.
    • QTc greater than 450 msec in men and 480 msec in women

    Repolarization abnormalities:

    • Acute medical condition that would make participation, in the opinion of the study physician, medically hazardous (e.g., unstable pancreatic, cardiovascular or renal disease, significant anemia)

  8. Known allergy or sensitivity to BUP, naloxone or MET or to any of the inactive ingredients in the study medications (including lactose, mannitol, cornstarch, povidone K30, citric acid, sodium citrate, FD&C Yellow No.6 color, magnesium stearate, Acesulfame K sweetener)
  9. Known diagnosis of acute psychosis, severe depression or imminent suicide risk as determined via clinical interview by study physician or surrogates
  10. DSM-IV diagnosis of dependence on alcohol requiring immediate medical attention.
  11. DSM-IV diagnosis of dependence on benzodiazepines requiring immediate medical attention
  12. DSM-IV diagnosis of dependence on other depressants, or stimulants requiring immediate medical attention
  13. Participation in an investigational drug study within the past 30 days
  14. Treatment with MET, BUP/NX, or BUP for more than 15 of the past 30 days (illicit use of these medications is allowed)
  15. Pending legal action that could prohibit study participation
  16. Unable or unwilling to comply with study requirements
  17. Unable or unwilling to remain in the local area for duration of treatment
  18. Poor venous access such that venipuncture could not be accomplished from a vein in an extremity during eligibility
  19. Pregnant or lactating (females only)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00315341

Locations
United States, California
Matrix Institute
Los Angeles, California, United States, 90016
Bi-Valley Medical Clinic INC.
Sacramento, California, United States, 95816
BAART; Turk Street Clinic
San Francisco, California, United States, 94102
United States, Connecticut
Hartford Dispensary
Hartford, Connecticut, United States, 06120
CT Counseling Centers
Waterbury, Connecticut, United States, 06705
United States, New York
Addiction Research & Treatment Corp
Brooklyn, New York, United States, 11201
United States, Oregon
CODA-Research
Portland, Oregon, United States, 97214
United States, Pennsylvania
NET Steps
Philadelphia, Pennsylvania, United States, 19137
United States, Washington
Evergreen Treatment Services
Seattle, Washington, United States, 98134
Sponsors and Collaborators
University of California, Los Angeles
National Institute on Drug Abuse (NIDA)
Investigators
Principal Investigator: Walter Ling, M.D. University of California, Los Angeles
Principal Investigator: Andrew Saxon, M.D. University of Washington
  More Information

Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Walter Ling, Principal Investigator, University of California, Los Angeles
ClinicalTrials.gov Identifier: NCT00315341     History of Changes
Other Study ID Numbers: NIDA-CTN-0027
U10DA013045 ( US NIH Grant/Contract Award Number )
Study First Received: April 16, 2006
Results First Received: May 17, 2013
Last Updated: November 9, 2016
Individual Participant Data  
Plan to Share IPD: No

Additional relevant MeSH terms:
Buprenorphine
Methadone
Buprenorphine, Naloxone Drug Combination
Naloxone
Analgesics, Opioid
Narcotics
Central Nervous System Depressants
Physiological Effects of Drugs
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Narcotic Antagonists
Antitussive Agents
Respiratory System Agents

ClinicalTrials.gov processed this record on April 21, 2017